Method for verifying whether sialic acid glycoform analysis result is accurate or not

By using protease enzyme digestion and acid hydrolysis after desaccharide in sialic acid sugar type analysis, the accuracy of sialic acid sugar type analysis results was confirmed, the problem of inappropriate pretreatment of complex glycoproteins was solved, and the analysis was improved The authenticity and representation of the results.

CN119086748AInactive Publication Date: 2024-12-06SHANGHAI AUSCON BIOPHARMACEUTICAL CO LTD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202411206080.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-30
Publication Date
2024-12-06
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

In the prior art, when analyzing the sialic acid sugar type of complex glycoproteins, it is difficult to accurately cut the sugar from the protein during the pretreatment process, resulting in the inaccurate detection results, especially for complex glycoprotein molecules with high sialylation, and sample pretreatment method. Not suitable, affecting the accuracy of the analysis results.

Method used

After desaccharification, protease enzyme cleavage and/or acid hydrolysis are carried out. By detecting whether the product is completely desaccharified, the accuracy of the sialic acid sugar type analysis results are confirmed, including the reaction using a mixed solution of guanidine hydrochloride and dithiothreitol, and the Enzyme cleavage or labeling reaction, combined with protease and acid solution treatment, ensure that the sugar in the glycoprotein is completely labeled.

Benefits of technology

The accuracy of the sialic acid sugar type analysis results was improved, the suitability of deglycemic conditions was evaluated, and it was suitable for glycoproteins with complex structures, ensuring that the data represents the true quality attributes of the molecule, reducing risks, and improving the characterization research plan.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119086748A_ABST
    Figure CN119086748A_ABST
Patent Text Reader

Abstract

The invention relates to a method for verifying whether a sialic acid glycotype analysis result is accurate or not, and the method for verifying whether the sialic acid glycotype analysis result is accurate or not comprises the following steps: carrying out desugaring, protease digestion and / or acid hydrolysis on glycoprotein by using a preset glycotype analysis method, and detecting whether the glycoprotein is completely desugarized or not so as to confirm whether the sialic acid glycotype analysis result is accurate or not, the glycoprotein contains sialic acid. According to the quality control method established by the invention, the analysis means of the current sialic acid sugar type-containing complex glycoprotein is perfected and improved, the accuracy of a detection result is ensured, and the quality control method is used for evaluating whether data can represent the real quality attribute of molecules or not, contributes to risk control and perfects a characterization research scheme.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of glycoform analysis, and in particular to a method for verifying whether a sialic acid glycoform analysis result is accurate, and in particular to a method for verifying whether a sialic acid glycoform analysis result of a complex glycoprotein is accurate. Background Art

[0002] Sugar-related characterization research methods mainly include molecular weight level analysis, glycopeptide level analysis, free sugar level analysis and sialic acid level analysis. The first three are qualitative analyses of glycosylation at the intact protein level, peptide level and free sugar level, respectively, focusing on the quality attributes of the samples and batch consistency. Sialic acid level analysis is a quantitative analysis, and its main purpose is to analyze the sialic acid content of glycoforms containing sialic acid. Research on the glycosylation of complex glycoproteins often requires a comprehensive analysis combining the above analytical methods to conduct qualitative and quantitative analyses of glycoforms from different dimensions.

[0003] Molecular weight analysis at the intact protein level and glycopeptide analysis at the peptide level are generally performed during characterization studies. Analysis at the free sugar level is often used as the main quality control method for release and process testing because of its short detection cycle and high throughput. The methods at the free sugar level mainly include protein denaturation, desugaring, sugar labeling and detection. For conventional monoclonal antibodies, there are relatively mature kit methods available for free sugar methods. However, for complex glycoproteins, especially highly sialylated complex glycoprotein molecules, the free sugar method poses higher challenges, which is mainly reflected in whether the sample pretreatment process can accurately cut the sugar from the protein, that is, whether the detected results are representative. If the sample pretreatment is not suitable and the sugar in the molecule cannot be completely labeled, the data obtained will not truly reflect the glycosylation level of the molecule.

[0004] CN117545851A discloses a method for analyzing sugar chains. The specific analysis method is as follows: (1) a freeing step, in which a sugar-cleaving enzyme is added to a sample containing an antibody to specifically free the sugar chains bound to the antibody to obtain free sugar chains; (2) a recovery step, in which the free sugar chains are recovered by affinity purification; (3) a hydrophobization step, in which the free sugar chains are hydrophobized to obtain hydrophobized sugar chains; and (4) a measurement step, in which the hydrophobized sugar chains are analyzed in sequence by supercritical liquid chromatography and tandem mass spectrometry.

[0005] In summary, how to select the glycoprotein pretreatment method for free sugar detection, especially glycoproteins with complex sugar structures, has become one of the urgent problems to be solved in this field. Summary of the invention

[0006] In order to solve the above technical problems, the present invention provides a method for verifying whether the results of sialic acid glycoform analysis are accurate. It is a perfection and improvement of the current analysis methods of glycoproteins containing sialic acid glycoforms, which ensures the accuracy of the test results and is used to evaluate whether the data can represent the true quality attributes of the molecule. It can also evaluate in advance the inapplicable methods, which is helpful for risk control and improvement of the characterization research plan.

[0007] To achieve this object, the present invention adopts the following technical solutions:

[0008] In a first aspect, the present invention provides a method for verifying whether the results of a sialic acid glycoform analysis are accurate, the method for verifying whether the results of a sialic acid glycoform analysis are accurate comprises: deglycosylating a glycoprotein using a preset glycoform analysis method, performing protease cleavage and / or acid hydrolysis, and detecting whether the deglycosylation is complete, thereby confirming whether the results of the sialic acid glycoform analysis are accurate, and the glycoprotein contains sialic acid.

[0009] In order to confirm whether the free sugar is completely deglycosylated and whether the sugar in the molecule is completely labeled during detection, that is, whether the sample pretreatment method is appropriate, especially whether the pretreatment method of highly sialylated complex glycoprotein molecules is appropriate, the present invention subjects the deglycosylated product to protease cleavage or acid hydrolysis, and confirms whether the sialic acid glycoform analysis result is accurate based on whether the product is completely deglycosylated.

[0010] The method provided by the present invention is particularly suitable for complex glycoproteins with complex structures and multiple sugar sites (such as unconventional monoclonal antibodies), samples containing multiple N-sugar and O-sugar sites, and a high proportion of sialic acid. Sialic acid is often a key quality attribute of the molecule and affects the efficacy. At the same time, for molecules whose sugar sites are not structurally exposed to the outside and denaturing sugar cleavage is not easy to cleave sugars, this type of verification method can better evaluate the applicability of desugaring conditions.

[0011] The method provided by the present invention is suitable for evaluating all types of glycoprotein glycoform analysis methods, specifically evaluating the applicability of glycoprotein deglycoform analysis methods, and more specifically evaluating whether the preset deglycoform analysis method can completely remove sugars from the glycoprotein to be tested, thereby confirming whether the sialic acid glycoform analysis results are accurate.

[0012] The following exemplifies some scenarios to which the present invention is applicable, such as the selection of methods and specific reagents for non-denaturing desugaring and denaturing desugaring, whether the buffer needs to be replaced before desugaring, the desugaring time and the use of desugaring enzymes (N-sugarase, N-sugar + O-sugarase, addition of sialidase), etc. It can be understood that the specific desugaring method is not a limitation of the present invention.

[0013] Preferably, the method for verifying whether the sialic acid glycoform analysis result is accurate specifically includes the following two methods:

[0014] (I) mixing the deglycosylated glycoprotein with guanidine hydrochloride and dithiothreitol to obtain a first mixed solution, performing a first reaction, mixing with iodoacetamide to obtain a second mixed solution, performing a second reaction, adding a replacement buffer on the flat membrane, adding a protease, performing an enzyme cleavage reaction, and detecting whether the deglycosylation is complete;

[0015] and / or (II) mixing the deglycosylated glycoprotein with an acid solution to obtain a third mixed solution, performing a third reaction, mixing with a labeling solution, performing a labeling reaction, and detecting whether the deglycosylation is complete.

[0016] In the actual evaluation process of the applicability of the glycoprotein glycoform analysis method, the method (I) and method (II) provided by the present invention can be used only one of them, or both methods can be used to detect the same deglycoprotein sample, and the two methods can be combined to obtain more comprehensive results.

[0017] Preferably, in method (I), the first mixed solution contains 5-7 M (for example, 5 M, 5.2 M, 5.4 M, 5.6 M, 5.8 M, 6 M, 6.2 M, 6.4 M, 6.6 M, 6.8 M or 7 M, etc.), pH 7-9 (for example, 7, 7.5, 8, 8.5 or 9, etc.) guanidine hydrochloride, 0.5-1.5 M (for example, 0.5 M, 0.7 M, 0.9 M, 1 M, 1.1 M, 1.3 M or 1.5 M, etc.) DTT and 0.5-5 mg / mL (for example, 0.5 mg / mL, 1 mg / mL, 2 mg / mL, 3 mg / mL, 4 mg / mL or 5 mg / mL, etc.) deglycoprotein.

[0018] Preferably, in method (I), the second mixed solution contains 0.5-1.5 M (eg, 0.5 M, 0.7 M, 0.9 M, 1 M, 1.1 M, 1.3 M or 1.5 M, etc.) iodoacetamide.

[0019] Preferably, the first reaction in method (I) is carried out at 50-60°C (for example, 50°C, 52°C, 54°C, 55°C, 56°C, 58°C or 60°C, etc.) for 25-35 min (for example, 25 min, 27 min, 29 min, 30 min, 31 min, 33 min or 35 min, etc.).

[0020] Preferably, the second reaction in method (I) is carried out at 20-30°C (for example, 20°C, 22°C, 24°C, 25°C, 26°C, 28°C or 30°C, etc.) for 40-50 min (for example, 40 min, 42 min, 44 min, 45 min, 46 min, 48 min or 50 min, etc.).

[0021] Preferably, the buffer in method (I) comprises 15-25 mM (for example, 15 mM, 18 mM, 20 mM, 22 mM or 25 mM, etc.) pH 7-9 (for example, 7, 7.5, 8, 8.5 or 9, etc.) Tris buffer.

[0022] Preferably, the protease in method (I) comprises any one of trypsin, aspartic protease, serine protease or chymotrypsin, or a combination of at least two thereof.

[0023] The type of protease used in the method (I) of the present invention depends on the specific sequence of the protein.

[0024] Preferably, the volume ratio of the protease to the deglycoprotein in method (I) is 1:(20-30).

[0025] The specific point values ​​of the above (20-30) can be selected as 20, 22, 24, 25, 26, 28 or 30, etc.

[0026] Preferably, the enzymatic cleavage reaction in method (I) is carried out at 30-45°C (for example, 30°C, 32°C, 35°C, 37°C, 40°C, 42°C or 45°C, etc.) for 14-18h (for example, 14h, 15h, 16h, 17h or 18h, etc.).

[0027] Preferably, the acid solution in method (II) comprises any one of hydrochloric acid, formic acid or acetic acid, or a combination of at least two of them.

[0028] Preferably, the third mixed solution in method (II) contains 0.04-0.06 M (for example, 0.04 M, 0.045 M, 0.05 M, 0.055 M or 0.06 M, etc.) HCl and 0.9-1 mg / mL (for example, 0.9 mg / mL, 0.92 mg / mL, 0.94 mg / mL, 0.95 mg / mL, 0.96 mg / mL, 0.98 mg / mL or 1 mg / mL, etc.) deglycoprotein.

[0029] Preferably, the third reaction in method (II) is carried out at 75-85°C (for example, 75°C, 77°C, 79°C, 80°C, 81°C, 83°C or 85°C, etc.) for 0.5-1.5h (for example, 0.5h, 0.7h, 0.9h, 1h, 1.1h, 1.3h or 1.5h, etc.).

[0030] Preferably, after the third reaction in method (II), the product is cooled, centrifuged at 4000-6000 g (for example, 4000 g, 4500 g, 5000 g, 5500 g or 6000 g, etc.) for 4-6 min (for example, 4 min, 4.5 min, 5 min, 5.5 min or 6 min, etc.), and the supernatant is taken.

[0031] Preferably, the volume ratio of the DMB solution, the coupling solution and water in the labeling solution in method (II) is 1:(4-6):(3-5).

[0032] The specific point values ​​of the above (4 to 6) can be selected as 4, 4.5, 5, 5.5 or 6, etc.

[0033] The specific point values ​​of the above (3-5) can be selected as 3, 3.5, 4, 4.5 or 5, etc.

[0034] Preferably, the volume ratio of the third mixed solution to the marking solution in method (II) is 1:(8-10).

[0035] The above (8-10) can be 8, 8.5, 9, 9.5 or 10, etc.

[0036] Preferably, the labeling reaction in method (II) is carried out in the dark at 45-55°C (for example, 45°C, 47°C, 49°C, 50°C, 51°C, 53°C or 55°C, etc.) for 2-3h (for example, 2h, 2.2h, 2.4h, 2.5h, 2.6h, 2.8h or 3h, etc.), and at 2-8°C (for example, 2°C, 3°C, 4°C, 5°C, 6°C, 7°C or 8°C, etc.) for 10-20min (for example, 10min, 12min, 14min, 15min, 16min, 18min or 20min, etc.) to terminate the reaction.

[0037] Preferably, after the labeling reaction in method (II), the method further includes the step of centrifuging at 4000-6000g (for example, 4000g, 4500g, 5000g, 5500g or 6000g, etc.) for 5-15min (for example, 5min, 7min, 9min, 10min, 11min, 13min or 15min, etc.) to obtain the supernatant.

[0038] Preferably, the detection method in method (I) includes the following two methods:

[0039] (i) loading the product onto a machine for glycopeptide analysis;

[0040] and / or (ii) concentrating the product under vacuum until liquid-free, and 18The labeled water and NH4HCO3 were mixed to obtain a fourth mixed solution, N-glycosamidase F was added to cleave the sugar, and the solution was acidified to a final formic acid concentration of 1% before loading onto the machine.

[0041] In the actual evaluation process of the applicability of the glycoprotein glycoform analysis method, the detection method (i) and the detection method (ii) provided by the present invention can be used only one of them, or both methods can be used to detect the same deglycoprotein sample, and the two methods can be combined to obtain more comprehensive results.

[0042] It is understandable that conventional glycopeptide analysis methods in the art are applicable to method (i) of the present invention. The specific glycopeptide analysis method does not have a limiting effect on the present invention. If no glycopeptide information is seen, it means that the desugaring effect is ideal. The higher the proportion of glycopeptides, the worse the desugaring effect.

[0043] The method (ii) provided by the present invention is to add O after the sample is concentrated to a liquid-free state. 18 The labeled water produced a mass change of 2.98 Da, which was reflected in the mass spectrometry data, and no O 18 The labeled peptide signal indicates that the desugaring is complete and contains O 18 The higher the proportion of labeled peptides, the worse the desugaring effect.

[0044] Preferably, method (I) further comprises centrifuging at 10-20°C (for example, 10°C, 12°C, 14°C, 15°C, 16°C, 18°C ​​or 20°C, etc.) at 12000-16000g (for example, 12000g, 12500g, 13000g, 13500g, 14000g, 14500g, 15000g, 15500g or 16000g, etc.) for 10-20min (for example, 10min, 12min, 14min, 15min, 16min, 18min or 20min, etc.) before detecting, and taking the supernatant.

[0045] Preferably, the fourth mixed solution in method (ii) contains 20-30 mM (for example, 20 mM, 22 mM, 24 mM, 25 mM, 26 mM, 28 mM or 30 mM, etc.) NH4HCO3.

[0046] Preferably, the detection method in method (II) comprises: using liquid chromatography to detect whether the product contains sialic acid.

[0047] In the detection results of the method (II) of the present invention, if the desugaring is good, no sialic acid signal should be detected. If a sialic acid signal is detected, a ratio can be calculated with the sample not involved in the desugaring test. The size of the ratio represents the proportion of sugar. The lower the ratio, the more ideal the desugaring effect.

[0048] Preferably, the liquid chromatography method comprises ultra-performance liquid chromatography (UPLC) and / or high performance liquid chromatography (HPLC).

[0049] Preferably, the mobile phase A of the liquid chromatography is 8% to 10% acetonitrile + 6% to 8% methanol, the mobile phase B is 95% to 100% acetonitrile, the column temperature is 28 to 32°C, the sample tray temperature is 2 to 8°C, the excitation wavelength of the fluorescence detector is 360 to 380nm, the emission wavelength is 440 to 460nm, and the injection volume is 8 to 12μL.

[0050] Preferably, the UPLC chromatographic column is C18 (2.1×150 mm, 1.7 μm) and the flow rate is 0.1 to 0.3 mL / min.

[0051] Preferably, the HPLC chromatographic column is C18 (4.6×150 mm, 4 μm) with a flow rate of 0.6 to 0.8 mL / min.

[0052] Preferably, the elution mode of the liquid chromatography is gradient elution, and the elution conditions are shown in Table 1.

[0053] Table 1

[0054]

[0055] Preferably, the detection using liquid chromatography also includes the step of establishing a standard curve for sialic acid content.

[0056] Compared with the prior art, the present invention has the following beneficial effects:

[0057] The present invention establishes a method for verifying whether the results of sialic acid glycoform analysis are accurate, which is a perfection and improvement of the current analysis methods of complex glycoproteins containing sialic acid glycoforms, ensuring the accuracy of the test results, and is used to evaluate whether the data can represent the true quality attributes of the molecule. In addition, inappropriate methods can be evaluated in advance, which is helpful for risk control and improving the characterization research plan. BRIEF DESCRIPTION OF THE DRAWINGS

[0058] Figure 1 TIC diagram for detecting the intact molecular weight of glycoprotein;

[0059] Figure 2 Detect raw mass spectra for intact molecular weight of glycoproteins;

[0060] Figure 3 TIC diagram for glycoprotein reduced molecular weight detection;

[0061] Figure 4 Detect raw mass spectra for glycoprotein reduced molecular weight;

[0062] Figure 5TIC diagram for the complete deglycosylation molecular weight test of glycoprotein;

[0063] Figure 6 Detect the original mass spectrum for the complete deglycosylated molecular weight of glycoproteins;

[0064] Figure 7 This is the result of the complete deglycosylation molecular weight test of glycoprotein;

[0065] Figure 8 This is the result diagram of glycoprotein and glycopeptide analysis;

[0066] Fig. 9 This is the result of mass spectrometry identification of free sugars;

[0067] Fig.10 The results of mass spectrometry identification of free sugars using different pre-treatment methods;

[0068] Fig.11 This is the standard curve of sialic acid content. DETAILED DESCRIPTION

[0069] To further illustrate the technical means and effects of the present invention, the present invention is further described below in conjunction with the embodiments and drawings. It should be understood that the specific implementation methods described herein are only used to explain the present invention, rather than to limit the present invention.

[0070] If no specific technology or condition is specified in the embodiment, the technology or condition described in the literature in this field or the product specification is used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels. In addition, the terms "first" and "second" are only used to distinguish in the description and have no special meaning.

[0071] Reagents used in the following examples:

[0072] Marking fluid: purchased from TaKaRa, product number 4400, prepared according to the product instructions.

[0073] Example 1

[0074] In this example, the molecular weight of the glycoprotein sample to be tested was analyzed at the intact protein level. Figure 1 The total ion current chromatogram (TIC graph) is used to detect the complete molecular weight of the sample. Figure 2 Detect the original mass spectrum for the sample's intact molecular weight, Figure 3 TIC diagram for sample reduction molecular weight detection. Figure 4 Restore the molecular weight of the sample to detect the original mass spectrum, Figure 5 This is the TIC diagram for the complete desugaring molecular weight detection of the sample. Figure 6 The original mass spectrum of the sample is used to detect the molecular weight of the complete desugaring. Figure 7This is the molecular weight test result of the sample after complete desugaring.

[0075] Combined with the molecular structure and amino acid information, this molecule was preliminarily evaluated as a relatively complex glycoprotein molecule. When the sample was subjected to complete molecular weight analysis, it was found that the original mass spectrum detected was relatively complex. It was speculated that this was mainly caused by the large number of sugar sites and complex sugar forms. In order to further verify the speculation, a desugaring test was carried out to confirm the molecular weight result after desugaring. The desugaring test found that this molecule could see relatively good molecular weight data after desugaring, which further verified the previous speculation. Based on the molecular weight level, it can be found that for such complex molecules, it is actually impossible to focus on sugar forms at the molecular weight level in some cases, depending on the complexity of the molecule. It also shows that this molecule is relatively complex, and it is necessary to pay attention to whether the desugaring conditions for the subsequent glycosylation analysis are tried and whether they can accurately characterize the quality attributes of the molecule.

[0076] Example 2

[0077] In this example, glycopeptide analysis was performed on glycoprotein samples. Figure 8 As shown, the common antibody Fc region glycoform information can be seen relatively well, and the consistency between samples is good, which can meet the needs of qualitative analysis. However, this method cannot meet the needs of sialic acid quantitative analysis.

[0078] Example 3

[0079] In this example, free sugar analysis was performed on glycoprotein samples. Fig. 9 It is the result of mass spectrometry identification of free sugars, which is used to identify each glycoform. The glycoform naming method is based on the naming of the database table in the BF data analysis software, where Ax is the number of antennae on the mannose core, Gx is the number of galactose attached to the antennae, F is fucose, and Sx is the number of sialic acids attached to galactose.

[0080] Fig.10 The free sugar detection results of two different pretreatment methods are compared. From the test results, it is found that the different pretreatment methods have a large difference in the results of free sugar identification. The main difference is reflected in the detection of highly complex sugar forms containing sialic acid. Through comparison, it is found that some pretreatment methods cannot completely remove sugars, and there are no other measures to prevent such risks. Therefore, based on such situations, the present invention establishes a solution to assist in judging the applicability of the method and to carry out risk assessment in advance.

[0081] Example 4

[0082] This embodiment provides a method for verifying whether the results of sialic acid glycoform analysis are accurate, which specifically includes the following steps:

[0083] (1) Take 100 μg of desugared glycoprotein, add guanidine hydrochloride with a pH of 7.8 to a final concentration of 6 M, then add DTT to a final concentration of 20 mM, react at 56°C for 30 min, and cool to room temperature;

[0084] (2) Add iodoacetamide to a final concentration of 50 mM and react at room temperature in the dark for 45 min;

[0085] (3) Take a 10KD flat membrane, add 20mM Tris buffer at pH7.8 to activate it, and centrifuge it at 15°C and 14000g for 15 min; add the above reaction sample to the activated 10KD flat membrane for replacement, and centrifuge it at 15°C and 14000g; pour off the liquid under the membrane, add Tris buffer to the membrane, and centrifuge it at 15°C and 14000g. Repeat this operation twice;

[0086] (4) Add trypsin, the volume ratio of protease to deglycoprotein is 1:25, the final volume of enzyme digestion is fixed to 50 μL reaction system, and digest at 37°C for 16 h;

[0087] (5) Centrifuge at 15°C, 14,000 g for 15 min, measure the OD value, and acidify before loading onto the centrifuge.

[0088] The samples to be tested are tested. If the sugar site has a high proportion of deamidation modification, it indicates that the site has a high proportion of glycosylation (+0.98 modification will exist after deglycosylation, and the software defaults to deamidation); if there is a certain low proportion of sugar signal, it means that most of the sugar has been removed. The specific amount of sugar that has not been removed needs to be combined with O 18 The water solution was used for further confirmation to exclude the influence of ionization of peptide map samples. The detection results are shown in Table 2.

[0089] Table 2

[0090]

[0091]

[0092] Example 5

[0093] This embodiment provides a method for verifying whether the results of sialic acid glycoform analysis are accurate, which specifically includes the following steps:

[0094] (1) to (4) are carried out with reference to Example 4;

[0095] (5) Centrifuge at 14,000 g for 15 min at 15°C, measure the OD value, and then concentrate under vacuum;

[0096] (6) Using O containing NH4HCO3 18The concentrated product was redissolved in water, the final concentration of NH4HCO3 was 25mM, the total volume was 50μL, N-glycosamidase F was added to cut the sugar for 2h, and the product was acidified to a final formic acid concentration of 1% before loading onto the machine.

[0097] The samples to be tested were tested, and the test results are shown in Table 3. Through the test, it was found that the molecule contained multiple glycosylation sites, and the sugar signals of different glycosylation sites were different, indicating that the pretreatment scheme of free sugar had different desugaring efficiencies for different sites.

[0098] Table 3

[0099] Location The proportion of sugars still contained in the enzyme-digested sample 1 0.00% 2 30.21% 3 32.82% 4 0.00%

[0100] Example 6

[0101] This embodiment provides a method for verifying whether the results of sialic acid glycoform analysis are accurate, which specifically includes the following steps:

[0102] (a) Add 20 μL of Gly-X denaturant to the bottom of the EP tube (if the sample pH is ≤5.5, add an additional 30 μL of Gly-X digestion buffer), then add 200 μL (2 mg / mL) of glycoprotein sample to the bottom of the EP tube, mix and centrifuge, and incubate at 90°C with the lid open for 3 min;

[0103] (b) After the incubation, remove the EP tube and place it at room temperature for 2 min (set another heater to 50°C), then add 20 μL of PNGase F working solution, gently mix and centrifuge, and incubate at 50°C with the lid open for 20-30 min;

[0104] (c) 10 kD vertical membrane centrifugation: After centrifugation at 14000 g twice, the lower liquid (containing N-glycan sialic acid) was removed, vacuum concentrated, and then reconstituted with 400 μL buffer;

[0105] (d) taking the stock solution, the sample above the 10KD membrane after the stock solution was desugared and replaced by the buffer solution, and the sample below the 10KD membrane after the stock solution was desugared and replaced by the buffer solution, and diluting them with ultrapure water to 1 mg / mL, with a total volume of 400 μL;

[0106] (e) Take 10 μL of 1M HCl and add it to a 1.5mL EP tube, then add 190 μL of the diluted sample, and take 190 μL of ultrapure water and treat it in the same way as the diluted sample as the acid hydrolysis blank; seal the EP tube with a sealing film, mix well and react in a metal bath at 80°C for 1 hour, then cool to room temperature and centrifuge at 5000g for 5 minutes;

[0107] (f) Take 20 μL of sample and add it to a 1.5 mL EP tube. Add 180 μL of labeling solution and mix well. Centrifuge at 5000 r for 5 min. Seal with sealing film and protect with aluminum foil to avoid light. Incubate in a metal bath at 50 °C for 2.5 h. Place the centrifuge tube at 4 °C for 15 min to terminate the labeling reaction. Centrifuge at 5000 g for 10 min. Take 20 μL of the sample supernatant after centrifugation and add 180 mL of ultrapure water to mix well.

[0108] (g) Sampling 100 μL into a sample injection vial, testing on an instrument, the conditions for testing on the instrument are shown in Table 4, and data analysis is performed;

[0109] Table 4

[0110]

[0111]

[0112] (h) Dilute the N-acetylneuraminic acid standard sample to 20 μg / mL, 10 μg / mL, 5 μg / mL, 2.5 μg / mL, 1.25 μg / mL, 0.625 μg / mL, 0.313 μg / mL, 0.156 μg / mL, and 0.078 μg / mL, respectively, and perform detection according to steps (f) and (g), and establish a standard curve, such as Fig.11 shown.

[0113] A value - the molar number of sialic acid calculated based on the concentration of the analyte;

[0114] B value - number of moles of protein;

[0115] Sialic acid content (mol / mol protein) = A / B.

[0116] This method was used to detect the sialic acid content of multiple different types of glycoproteins. The results are shown in Table 5. Various samples were not completely deglycosylated.

[0117] Table 5

[0118]

[0119]

[0120] This Example 6 shows that the total sialic acid content in the sample is not lost, that is, the total amount of sialic acid above and below the 10KD membrane is consistent with the sialic acid content of the original solution. It also illustrates the applicability of the sialic acid content method. By examining the total amount of sialic acid before and after replacement, it also provides a verification idea for sialic acid characterization analysis.

[0121] In summary, the present invention has established a quality control method for verifying whether the results of sialic acid glycoform analysis are accurate. The method is applicable to complex glycoproteins, especially highly sialylated complex glycoprotein molecules. It is a perfection and improvement of the current analysis methods of glycoproteins containing sialic acid glycoforms, ensuring the accuracy of the test results. It is used to evaluate whether the data can represent the true quality attributes of the molecules, and can evaluate in advance for inapplicable methods, which is helpful for risk control and improvement of characterization research programs.

[0122] The applicant declares that the above is only a specific implementation mode of the present invention, but the protection scope of the present invention is not limited thereto. Those skilled in the art should understand that any changes or substitutions that can be easily thought of by those skilled in the art within the technical scope disclosed by the present invention shall fall within the protection scope and disclosure scope of the present invention.

Claims

1. A method for verifying whether the results of sialic acid glycoform analysis are accurate, characterized in that: The method for verifying whether the sialic acid glycoform analysis result is accurate comprises: deglycosylating the glycoprotein using a preset glycoform analysis method, enzymatically cleaving with a protease and / or hydrolyzing with an acid, and detecting whether the deglycosylation is complete, thereby confirming whether the sialic acid glycoform analysis result is accurate, and the glycoprotein contains sialic acid.

2. The method for verifying whether the results of sialic acid glycoform analysis are accurate according to claim 1, characterized in that: The method for verifying whether the sialic acid glycoform analysis result is accurate specifically includes the following two methods: (I) mixing the deglycosylated glycoprotein with guanidine hydrochloride and dithiothreitol to obtain a first mixed solution, performing a first reaction, mixing with iodoacetamide to obtain a second mixed solution, performing a second reaction, adding a replacement buffer on the flat membrane, adding a protease, performing an enzyme cleavage reaction, and detecting whether the deglycosylation is complete; and / or (II) mixing the deglycosylated glycoprotein with an acid solution to obtain a third mixed solution, performing a third reaction, mixing with a labeling solution, performing a labeling reaction, and detecting whether the deglycosylation is complete.

3. The method for verifying whether the sialic acid glycoform analysis result is accurate according to claim 2, characterized in that: In method (I), the first mixed solution contains 5-7 M guanidine hydrochloride at pH 7-9, 0.5-1.5 M dithiothreitol and 0.5-5 mg / mL desugared glycoprotein; Preferably, in method (I), the second mixed solution contains 0.5-1.5 M iodoacetamide; Preferably, in method (I), the first reaction is carried out at 50-60°C for 25-35 minutes; Preferably, the second reaction in method (I) is carried out at 20-30°C for 40-50 minutes; Preferably, the buffer in method (I) comprises 15-25 mM pH 7-9 Tris buffer.

4. The method for verifying whether the results of sialic acid glycoform analysis are accurate according to claim 2, characterized in that: The protease in method (I) includes any one of trypsin, aspartic protease, serine protease or chymotrypsin, or a combination of at least two thereof; Preferably, the volume ratio of the protease to the deglycosylated glycoprotein in method (I) is 1:(20-30); Preferably, the enzymatic digestion reaction in method (I) is carried out at 30-45°C for 14-18 hours.

5. The method for verifying whether the results of sialic acid glycoform analysis are accurate according to claim 2, characterized in that: The acid solution in method (II) comprises any one of hydrochloric acid, formic acid or acetic acid, or a combination of at least two thereof; Preferably, the third mixed solution in method (II) contains 0.04-0.06M HCl and 0.9-1 mg / mL deglycoprotein; Preferably, the third reaction in method (II) is carried out at 75-85°C for 0.5-1.5h; Preferably, after the third reaction in method (II), the product is cooled, centrifuged at 4000-6000 g for 4-6 min, and the supernatant is collected.

6. The method for verifying whether the result of sialic acid glycoform analysis is accurate according to any one of claims 2 to 5, characterized in that: The volume ratio of DMB solution, coupling solution and water in the labeling solution in method (II) is 1:(4-6):(3-5); Preferably, the volume ratio of the third mixed solution to the marking solution in method (II) is 1:(8-10); Preferably, the labeling reaction in method (II) is carried out at 45-55°C in the dark for 2-3 hours, and the reaction is terminated at 2-8°C for 10-20 minutes; Preferably, after the labeling reaction in method (II), the method further comprises the step of centrifuging at 4000-6000 g for 5-15 min and collecting the supernatant.

7. The method for verifying whether the results of sialic acid glycoform analysis are accurate according to any one of claims 2 to 6, characterized in that: The detection methods described in method (I) include the following two methods: (i) loading the product onto a machine for glycopeptide analysis; and / or (ii) concentrating the product under vacuum until it is free of liquid, and 18 The labeled water and NH4HCO3 were mixed to obtain a fourth mixed solution, N-glycosamidase F was added to cleave the sugar, and the solution was acidified to a final formic acid concentration of 1% before loading onto the machine.

8. The method for verifying whether the results of sialic acid glycoform analysis are accurate according to any one of claims 2 to 7, characterized in that: Before the detection in method (I), the method further comprises centrifuging at 12000-16000 g for 10-20 min at 10-20° C. and taking the supernatant; Preferably, the fourth mixed solution in method (ii) contains 20-30 mM NH4HCO3.

9. The method for verifying whether the results of sialic acid glycoform analysis are accurate according to any one of claims 2 to 8, characterized in that: The detection method described in method (II) includes: using a liquid chromatography method to detect whether the product contains sialic acid.

10. The method for verifying whether the results of sialic acid glycoform analysis are accurate according to claim 9, characterized in that: The detection by liquid chromatography also includes the step of establishing a standard curve of sialic acid content.

Citation Information

Patent Citations

  • Method for analyzing sugar chain

    CN117545851A

  • Glycoprotein group quantitating method by lectin enriching and <18>O marking combined custom algorithm

    CN102590376A

  • Pharmacokinetic research mass spectrometry method for rituximab

    CN111239273A